Klee Justin B. sold 37,483 shares of Amylyx Pharmaceuticals, Inc. at $29.39 for −$1.10M on Nov 9, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Co-Chief Executive Officer
Co-Chief Executive Officer
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,101,689.09Shares × reported price
Shares traded
37,483Common Stock
Price per share
$29.39Reported price. Read footnotes for ranges.
% of reported position traded
1.04%This security and ownership context
Holdings after
3,575,573Direct
Trade date
Nov 9, 2026Sell
Filed
Nov 12, 2026, 4:00 PM ET3-day reporting delay
Accession
0001193125-26-458246Code S · Transaction 398622
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 3,613,056 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Sell62,517$30.11−$1,882,149.31Trade 398623
2 transaction rows in this filing. Joint filers share the same rows.

AMLX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
AMLX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +1.9%1w ago +1.5%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.72 to $29.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.